# Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

> **NCT06042257** · PHASE2 · TERMINATED · sponsor: **Rachel G. Greenberg, MD, MB, MHS** · enrollment: 3 (actual)

## Conditions studied

- Hyperactivity in Children With Down Syndrome
- Impulsivity in Children With Down Syndrome

## Interventions

- **DRUG:** Guanfacine Hydrochloride Immediate Release
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06042257
- **Lead sponsor:** Rachel G. Greenberg, MD, MB, MHS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-09
- **Primary completion:** 2025-05-17
- **Final completion:** 2025-08-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study was stopped after careful review of product manufacturing needs and available resources. Decision reflects consideration of feasibility, enrollment challenges, and overall program goals.
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06042257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06042257, "Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06042257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*